Free Newsletter
Eli Lilly settles Connecticut Zyprexa suit
Eli Lilly has settled yet another state lawsuit over the mismarketing of antipsychotic drug Zyprexa. The Indianapolis-based drugmaker has agreed to pay Connecticut $25 million for marketing Zyprexa for unapproved uses, including dementia and attention-deficit disorder. That off-labeling marketing, says Attorney General Richard Blumenthal, caused some patients to gain weight, develop diabetes and cardiovascular problems, among other side effects.
A total of 13 states filed claims against Lilly over its off-labeling marketing of Zyprexa. The company has already closed deals with Alaska and West Virginia. More settlements are expected to be announced soon as Lilly said in July that it would take a pretax charge of $102 million in Q3 for settling "several" state lawsuits and earlier this month the drugmaker said it had resolved claims with seven states, Bloomberg reports.
- more from Bloomberg
Related Articles:
Lilly nears another Zyprexa settlement
Lilly 'ghostwrote' Zyprexa studies, documents show
Lilly balks at AG's $2B Zyprexa suit
Lilly to pay $1.4B in Zyprexa settlement
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: